On the stock market since 2015, it operates in the world of health and science. It has 35 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $126.8M in the vault; even if every debt were paid off, $126.4M would remain.
The average analyst price target is $9.50 — 4,622% above today’s price.
It pays out $1.69 per share each year — regular cash for whoever holds the stock.
A loss of $28.5M against $0 in annual sales.
The stock sits at $0.20. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 12 months, executives reported 13 sells against just 4 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, EPIX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EPIX is a high-risk stock — not yet profitable, and its future rides on its product catching on.